[Tailor-made medicine in Helicobacter pylori eradication therapy].
Pharmacokinetic profiles of omeprazole and lansoprazole were well correlated with the CYP2C19 genotype. The heterozygous extensive metabolizer was slightly different from the homozygote, but there was no statistically significant difference. The CYP2C19 genotype dependence found for lansoprazole was not obvious compared with omeprazole. As for rabeprazole, the pharmacokinetic profile was independent of the CYP2C19 genotype. CYP2C19 genotyping can provide a new strategy to choose an optimal regimen, and this genotyping is especially useful for Japanese, as the frequency of poor metabolizers is five times greater than that found among Caucasians. However, we should be aware that the increase of antimicrobial-resistant strains of H. pylori may force us to examine antimicrobial susceptibility of all patients in order to achieve a more than 80% eradication rate at first-line therapy in the near future. We should also have proper knowledge of the influence of the CYP2C19 genetic polymorphism on treatment efficacy according to the variety of PPI and the combination with other drugs.
Aoyama
Nobuo
N
Department of Endoscopy, Kobe University School of Medicine.
Shirasaka
Daisuke
D
Miki
Ikuya
I
D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065731:Cytochrome P-450 CYP2C19; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000276:immunology*; D016480:Helicobacter pylori; D006801:Humans; D006899:Mixed Function Oxygenases / Q000235:genetics*; D009853:Omeprazole / Q000378:metabolism* / Q000627:therapeutic use*; D011110:Polymorphism, Genetic
D006899:Mixed Function Oxygenases; D001189:Aryl Hydrocarbon Hydroxylases; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D009853:Omeprazole